副腎皮質ステロイド療法市場：タイプ、投与経路、用途別-2025-2030年の世界予測

副腎皮質ステロイド療法市場は、2023年に49億7,000万米ドルと評価され、2024年には52億6,000万米ドルに達すると予測され、CAGR 7.48％で成長し、2030年には82億4,000万米ドルに達すると予測されています。

コルチコステロイド療法は、副腎皮質から自然に分泌されるホルモンであるコルチゾールを模倣した合成薬を使用して、炎症を抑え、免疫系を抑制するものです。コルチコステロイドは、関節炎、アレルギー反応、喘息、自己免疫疾患、さらには特定のがんなど、多くの疾患の治療に不可欠であり、医療介入におけるその必要性を物語っています。これらの薬剤は、局所的、経口的、または静脈内に適用され、主に病院やクリニック、製薬会社、研究大学などのヘルスケア機関で最終用途を見出します。市場の成長要因としては、慢性疾患の有病率の上昇、自己免疫疾患に対する意識の高まり、ドラッグデリバリーシステムの進歩などが挙げられます。さらに、新興国におけるヘルスケア・インフラの拡充は有利な機会をもたらします。しかし、感染リスクの増加や長期使用による骨の弱体化といった副作用の可能性、規制上の課題、薬剤耐性の開拓といった課題は、市場の成長を阻害する可能性があります。こうしたビジネスチャンスを生かすため、企業は安全性プロファイルを改善した副腎皮質ステロイドの開発と個別化医療アプローチに注力すべきです。吸入器や経皮パッチのような新規ドラッグデリバリー・システムの革新は、有効性を高め、副作用を最小限に抑える可能性があります。さらに、副腎皮質ステロイドの非ゲノム経路の研究は、革新的な治療への道を開く可能性があります。研究機関との戦略的提携は、製品パイプラインを充実させ、進歩を加速させる可能性があります。また、規制の変更を監視し、コンプライアンスに機敏に対応することで、競争上の優位性を得ることもできます。コルチコステロイド療法市場はダイナミックで、ヘルスケア政策や科学的イノベーションの変動と密接に結びついています。企業は、研究開発において積極的なアプローチを採用し、遺伝子に沿った治療法に焦点を当て、デジタルヘルス技術を活用して個別化治療戦略をサポートする必要があります。課題を効果的に克服し、オーダーメイドのヘルスケアソリューションに対する需要の高まりを取り込むことで、企業はこの進化する市場において成長を維持し、拡大することができます。

市場力学：急速に進化する副腎皮質ステロイド療法市場の主要市場インサイトを公開

副腎皮質ステロイド療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 炎症性疾患および自己免疫疾患の有病率の増加
  • 利便性と有効性が向上したドラッグデリバリーシステムの利用可能性
  • コルチコステロイドの感染症治療への応用
• 市場抑制要因
  • 代替療法の利用可能性
• 市場機会
  • 新規の注射用担体ベースのコルチコステロイド療法のイントロダクション
  • 単回吸入コルチコステロイド療法の改善
• 市場の課題
  • コルチコステロイド療法に伴う副作用

ポーターの5つの力：副腎皮質ステロイド療法市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：副腎皮質ステロイド療法市場における外部からの影響の把握

外部マクロ環境要因は、副腎皮質ステロイド療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析副腎皮質ステロイド療法市場における競合情勢の把握

副腎皮質ステロイド療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス副腎皮質ステロイド療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、副腎皮質ステロイド療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨副腎皮質ステロイド療法市場における成功への道筋を描く

副腎皮質ステロイド療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 炎症性疾患および自己免疫疾患の罹患率の増加
    • 利便性と有効性が向上したドラッグデリバリーシステムの利用可能性
    • 感染症におけるコルチコステロイド療法の治療応用
  • 抑制要因
    • 代替療法の利用可能性
  • 機会
    • 新規注射用キャリアベースコルチコステロイド療法のイントロダクション
    • 単剤吸入ステロイド療法の改善
  • 課題
    • コルチコステロイド療法に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 副腎皮質ステロイド療法市場：タイプ別

• グルココルチコイド
• ミネラルコルチコイド

第7章 副腎皮質ステロイド療法市場：投与経路別

• 吸入
• オーラル
• 全身的
• 話題

第8章 副腎皮質ステロイド療法市場：用途別

• 急性呼吸器疾患
• 内分泌学
• 消化器内科
• リウマチ学
• 皮膚アレルギー

第9章 南北アメリカの副腎皮質ステロイド療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の副腎皮質ステロイド療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの副腎皮質ステロイド療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Allergan PLC by AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Galderma Group
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• SANTHERA PHARMACEUTICALS
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. CORTICOSTEROIDS THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. CORTICOSTEROIDS THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CORTICOSTEROIDS THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CORTICOSTEROIDS THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY MINERALOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ACUTE RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SKIN ALLERGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Corticosteroids Therapy Market was valued at USD 4.97 billion in 2023, expected to reach USD 5.26 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 8.24 billion by 2030.

Corticosteroid therapy involves using synthetic drugs that mimic cortisol-a hormone naturally produced by the adrenal cortex, to reduce inflammation and suppress the immune system. They are critical in treating numerous conditions like arthritis, allergic reactions, asthma, autoimmune disorders, and even certain cancers, underscoring their necessity in medical interventions. These drugs are applied topically, orally, or intravenously and find end-use primarily in healthcare institutions such as hospitals and clinics, pharmaceuticals, and research universities. Market growth factors include the rising prevalence of chronic diseases, increasing awareness about autoimmune diseases, and advancements in drug delivery systems. Furthermore, expansions in healthcare infrastructure in emerging economies present lucrative opportunities. However, challenges such as potential side effects, like increased risk of infection and weakening of bones upon prolonged use, regulatory challenges, and the development of drug resistance may impede market growth. To capitalize on these opportunities, businesses should focus on developing corticosteroids with improved safety profiles and personalized medicine approaches. Innovations in novel drug delivery systems, like inhalers or transdermal patches, could enhance efficacy and minimize side effects. Furthermore, research into non-genomic pathways of corticosteroids could pave the way for innovative therapies. Strategic collaborations with research institutions could enrich product pipelines and accelerate advancements. Monitoring regulatory changes and being agile in compliance can also provide competitive advantages. The corticosteroid therapy market is dynamic, closely tied to fluctuations in healthcare policies and scientific innovations. Companies need to adopt a proactive approach in research and development, focusing on genetically aligned treatments and leveraging digital health technologies to support personalized therapeutic strategies. By effectively navigating the challenges and tapping into the growing demand for tailored healthcare solutions, companies can sustain growth and expand within this evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Corticosteroids Therapy Market

The Corticosteroids Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of inflammatory and autoimmune diseases
  • Availability of drug delivery systems with improved convenience and efficacy
  • Therapeutic applications of corticosteroids-therapy in infectious diseases
• Market Restraints
  • Availability of alternative therapies
• Market Opportunities
  • Introduction of novel injectable carrier-based corticosteroid therapy
  • Improvements in single-entity inhaled corticosteroid therapy
• Market Challenges
  • Adverse effects associated with corticosteroids-therapy

Porter's Five Forces: A Strategic Tool for Navigating the Corticosteroids Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Corticosteroids Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Corticosteroids Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Corticosteroids Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Corticosteroids Therapy Market

A detailed market share analysis in the Corticosteroids Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Corticosteroids Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Corticosteroids Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Corticosteroids Therapy Market

A strategic analysis of the Corticosteroids Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Corticosteroids Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan PLC by AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Galderma Group, Gilead Sciences, Inc., GlaxoSmithKline PLC, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., SANTHERA PHARMACEUTICALS, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Corticosteroids Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Glucocorticoids and Mineralocorticoids.
• Based on Route of Administration, market is studied across Inhaled, Oral, Systemic, and Topical.
• Based on Application, market is studied across Acute Respiratory Diseases, Endocrinology, Gastroenterology, Rheumatology, and Skin Allergies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of inflammatory and autoimmune diseases
    • 5.1.1.2. Availability of drug delivery systems with improved convenience and efficacy
    • 5.1.1.3. Therapeutic applications of corticosteroids-therapy in infectious diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Availability of alternative therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of novel injectable carrier-based corticosteroid therapy
    • 5.1.3.2. Improvements in single-entity inhaled corticosteroid therapy
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with corticosteroids-therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Corticosteroids Therapy Market, by Type

• 6.1. Introduction
• 6.2. Glucocorticoids
• 6.3. Mineralocorticoids

7. Corticosteroids Therapy Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhaled
• 7.3. Oral
• 7.4. Systemic
• 7.5. Topical

8. Corticosteroids Therapy Market, by Application

• 8.1. Introduction
• 8.2. Acute Respiratory Diseases
• 8.3. Endocrinology
• 8.4. Gastroenterology
• 8.5. Rheumatology
• 8.6. Skin Allergies

9. Americas Corticosteroids Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Corticosteroids Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Corticosteroids Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Allergan PLC by AbbVie Inc.
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. Biogen Inc.
• 6. Boehringer Ingelheim GmbH
• 7. Bristol-Myers Squibb Company
• 8. Cipla Inc.
• 9. Dr. Reddy's Laboratories Ltd.
• 10. Eli Lilly and Company
• 11. Galderma Group
• 12. Gilead Sciences, Inc.
• 13. GlaxoSmithKline PLC
• 14. Lupin Pharmaceuticals, Inc.
• 15. Merck & Co., Inc.
• 16. Mylan N.V.
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Sanofi S.A.
• 20. SANTHERA PHARMACEUTICALS
• 21. Sun Pharmaceutical Industries Ltd.
• 22. Takeda Pharmaceutical Company Limited
• 23. Teva Pharmaceutical Industries Ltd.